Clinical Trial Update: Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) [Phase 3]

View source ↗

Summary

Phase 3 NOR-MS trial evaluating oral cladribine in combination with rituximab for relapsing multiple sclerosis has completed. The study investigates a combinati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)
• Rituxan (rituximab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Status: COMPLETED